Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat

Stroke

Volumn 45, Issue 8, 2014, Pages 2404-2410

  Kono, Syoichiro ^a   Yamashita, Toru ^a   Deguchi, Kentaro ^a   Omote, Yoshio ^a   Yunoki, Taijun ^a   Sato, Kota ^a   Kurata, Tomoko ^a   Hishikawa, Nozomi ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

apixaban; intracranial hemorrhages; pericytes; rivaroxaban; thrombolytic therapy; tissue type plasminogen activator

Indexed keywords

ALTEPLASE; APIXABAN; GELATINASE B; PLACEBO; RIVAROXABAN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BASEMENT MEMBRANE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PARAPLEGIA; PERICYTE; PRIORITY JOURNAL; RAT;

APIXABAN; INTRACRANIAL HEMORRHAGES; PERICYTES; RIVAROXABAN; THROMBOLYTIC THERAPY; TISSUE-TYPE PLASMINOGEN ACTIVATOR;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BRAIN; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; INTRACRANIAL HEMORRHAGES; MALE; MORPHOLINES; PYRAZOLES; PYRIDONES; RATS; RATS, WISTAR; STROKE; THIOPHENES; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84905391822     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005316     Document Type: Article

References (36)

1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
3. Prabhakaran S, Rivolta J, Vieira JR, Rincon F, Stillman J, Marshall RS, et al. Symptomatic intracerebral hemorrhage among eligible warfarintreated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010;67:559-563.
4. Seet RC, Zhang Y, Moore SA, Wijdicks EF, Rabinstein AA. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2011;42:2333-2335.
5. Levin D, Smith DB, Cumbler E, Carter J, Glasheen JJ, Jones W. Warfarin therapy does not increase risk of symptomatic intracerebral hemorrhage in eligible patients after intravenous thrombolysis. Arch Neurol. 2011;68:135, author reply 135-135, author reply 136.
6. Vergouwen MD, Casaubon LK, Swartz RH, Fang J, Stamplecoski M, Kapral MK, et al; Investigators of the Registry of the Canadian Stroke Network. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke. 2011;42:1041-1045.
7. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012;307:2600-2608.
8. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al; J-MARS Investigators. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010;41:1984-1989.
9. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521.
10. Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, et al. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006;4:1989-1996.
11. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98:333-338.
12. Schumacher WA, Bostwick JS, Stewart AB, Steinbacher TE, Xin B, Wong PC. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol. 2010;55:609-616.
13. Abe K, Kawagoe J, Araki T, Aoki M, Kogure K. Differential expression of heat shock protein 70 gene between the cortex and caudate after transient focal cerebral ischaemia in rats. Neurol Res. 1992;14:381-385.
14. Kitagawa H, Sasaki C, Sakai K, Mori A, Mitsumoto Y, Mori T, et al. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 1999;19:1336-1344.
15. Kono S, Deguchi K, Omote Y, Yunoki T, Yamashita T, Kurata T, et al. Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat. J Neurosci Res. 2014;92:46-53.
16. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Shang J, et al. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res. 2011;1368:317-323.
17. Wu J, Hua Y, Keep RF, Nakamura T, Hoff JT, Xi G. Iron and ironhandling proteins in the brain after intracerebral hemorrhage. Stroke. 2003;34:2964-2969.
18. Augustin HG, Braun K, Telemenakis I, Modlich U, Kuhn W. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol. 1995;147:339-351.
19. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York, NY: Academic Press; 1982.
20. Omori N, Jin G, Li F, Zhang WR, Wang SJ, Hamakawa Y, et al. Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Res. 2002;954:317-322.
21. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab. 2009;29:715-725.
22. Kawiorski MM, Alonso-Canovas A, de Felipe Mimbrera A, Sainz de la Maza S, Alvarez-Velasco R, Zarza B, et al. Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment. Thromb Haemost. 2014;111:557-558.
23. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133-139.
24. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776-786.
25. Aschner JL, Lum H, Fletcher PW, Malik AB. Bradykinin- and thrombininduced increases in endothelial permeability occur independently of phospholipase C but require protein kinase C activation. J Cell Physiol. 1997;173:387-396.
26. Kamiya T, Katayama Y, Kashiwagi F, Terashi A. The role of bradykinin in mediating ischemic brain edema in rats. Stroke. 1993;24:571-575, discussion 575.
27. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39:279-291.
28. Suarez S, Ballmer-Hofer K. VEGF transiently disrupts gap junctional communication in endothelial cells. J Cell Sci. 2001;114(pt 6):1229-1235.
29. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH. Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol. 2006;59:929-938.
30. del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879-894.
31. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2:502-511.
32. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36:1954-1959.
33. Klohs J, Steinbrink J, Bourayou R, Mueller S, Cordell R, Licha K, et al. Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel method for non-invasive optical imaging of blood-brain barrier impairment after focal cerebral ischemia in mice. J Neurosci Methods. 2009;180:126-132.
34. Yagi K, Kitazato KT, Uno M, Tada Y, Kinouchi T, Shimada K, et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke. 2009;40:626-631.
35. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med. 2009;15:1031-1037.
36. Fisher MJ. Brain regulation of thrombosis and hemostasis: from theory to practice. Stroke. 2013;44:3275-3285.